Close Menu

A Pretty Nice Pasture

The former president of product development at Genentech, Susan Desmond-Hellmann, will be taking up a chancellor post at the University of California, San Francisco, after the Board of Regents votes on her appointment later this week, reports the WSJ Health Blog. Before joining Genentech, Desmond-Hellman trained at UCSF, then practiced as an oncologist. At Genentech, she oversaw the development of Avastin, Herceptin, and Rituxan.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.